BioCryst Pharmaceuticals raised its full-year 2026 total revenue guidance to a range of $690 million to $715 million, driven by the closing of a navenibart European license agreement. The company maintained its ORLADEYO revenue guidance of $625 million to $645 million and reduced its non-GAAP operating cost guidance to $420 million to $440 million from a prior range of $450 million to $470 million. Second-quarter ORLADEYO revenue reached $158.2 million, contributing to a non-GAAP operating profit of $113.2 million. The company also began shipping ORLADEYO oral pellets for pediatric patients and reported 47 prescriptions through July 31, ahead of full-year expectations. BioCryst ended the quarter with over $350 million in cash, cash equivalents, and investments, and generated positive cash flow even excluding upfront proceeds from the license agreement.
BioCryst Pharmaceuticals IncRaised 2026 revenue guidance and reduced cost guidance, with strong Q2 results and positive cash flow.
